59 related articles for article (PubMed ID: 15217946)
1. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.
Boldrini L; Ursino S; Gisfredi S; Faviana P; Donati V; Camacci T; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4101-8. PubMed ID: 15217946
[TBL] [Abstract][Full Text] [Related]
2. No detection of c-kit gene mutations in exons 9, 11, 13 and 17 and low CD117 expression in plaque-stage mycosis fungoides.
Luca DA; Enz PA; Galimberti RL; Rinflerch AR
An Bras Dermatol; 2018; 93(6):913-915. PubMed ID: 30484546
[TBL] [Abstract][Full Text] [Related]
3. Kit Use May Not Be Key to Improved Prognosis.
Goto T
J Thorac Oncol; 2023 Aug; 18(8):e79-e80. PubMed ID: 37479330
[No Abstract] [Full Text] [Related]
4. Somatic mutation of KIT is rare in small cell lung cancer patients from Northeast China.
Xuan H; Jingshu G; Fang Y; Na L; Xiaolin S; Zhaoyang Y; Meng W; Gongyan C
Histol Histopathol; 2014 Feb; 29(2):273-8. PubMed ID: 23965952
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis type-1 is a prognostic indicator in human gastric carcinoma.
Liu D; Zhang Y; Li Y; Fan K
Oncotarget; 2017 Oct; 8(47):82910-82919. PubMed ID: 29137312
[TBL] [Abstract][Full Text] [Related]
6. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Cirenajwis H; Lauss M; Ekedahl H; Törngren T; Kvist A; Saal LH; Olsson H; Staaf J; Carneiro A; Ingvar C; Harbst K; Hayward NK; Jönsson G
Mol Oncol; 2017 Apr; 11(4):438-451. PubMed ID: 28267273
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases.
Read WL; Williams F
Case Rep Oncol; 2016; 9(3):639-643. PubMed ID: 27920695
[TBL] [Abstract][Full Text] [Related]
8. Reduction of the Renal Radioactivity of
Suzuki H; Araki M; Tatsugi K; Ichinohe K; Uehara T; Arano Y
J Med Chem; 2023 Jul; 66(13):8600-8613. PubMed ID: 37322876
[TBL] [Abstract][Full Text] [Related]
9. c-kit2 G-quadruplex stabilized via a covalent probe: exploring G-quartet asymmetry.
Peterková K; Durník I; Marek R; Plavec J; Podbevšek P
Nucleic Acids Res; 2021 Sep; 49(15):8947-8960. PubMed ID: 34365512
[TBL] [Abstract][Full Text] [Related]
10. A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.
Yan F; Shen N; Pang J; Zhao N; Deng B; Li B; Yang Y; Yang P; Molina JR; Liu S
Oncogene; 2017 Dec; 36(50):6919-6928. PubMed ID: 28869603
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker.
Yokouchi H; Nishihara H; Harada T; Ishida T; Yamazaki S; Kikuchi H; Oizumi S; Uramoto H; Tanaka F; Harada M; Akie K; Sugaya F; Fujita Y; Takamura K; Kojima T; Higuchi M; Honjo O; Minami Y; Watanabe N; Goto A; Suzuki H; Dosaka-Akita H; Isobe H; Nishimura M; Munakata M
Oncotarget; 2017 Jun; 8(24):39711-39726. PubMed ID: 28055980
[TBL] [Abstract][Full Text] [Related]
12. Targeted drugs in small-cell lung cancer.
Santarpia M; Daffinà MG; Karachaliou N; González-Cao M; Lazzari C; Altavilla G; Rosell R
Transl Lung Cancer Res; 2016 Feb; 5(1):51-70. PubMed ID: 26958493
[TBL] [Abstract][Full Text] [Related]
13. Detection of c-kit mutational status in small-cell lung cancer in a Chinese cohort.
Cheng Y; Li H; Ma L; Zhang S; Yan S; Zhu J; Wang S; Zhang R; Niu K; Liu Y
Thorac Cancer; 2014 May; 5(3):225-31. PubMed ID: 26767005
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer biomarkers, targeted therapies and clinical assays.
Patel JN; Ersek JL; Kim ES
Transl Lung Cancer Res; 2015 Oct; 4(5):503-14. PubMed ID: 26629419
[TBL] [Abstract][Full Text] [Related]
15. The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
Yan F; Shen N; Pang J; Molina JR; Yang P; Liu S
J Biol Chem; 2015 Jul; 290(30):18480-94. PubMed ID: 26085088
[TBL] [Abstract][Full Text] [Related]
16. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
Venook AP; Arcila ME; Benson AB; Berry DA; Camidge DR; Carlson RW; Choueiri TK; Guild V; Kalemkerian GP; Kurzrock R; Lovly CM; McKee AE; Morgan RJ; Olszanski AJ; Redman MW; Stearns V; McClure J; Birkeland ML
J Natl Compr Canc Netw; 2014 Nov; 12(11):1629-49. PubMed ID: 25361808
[TBL] [Abstract][Full Text] [Related]
17. Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer.
Xiao H; Wang J; Liu Y; Li L
Oncol Lett; 2014 Aug; 8(2):582-588. PubMed ID: 25013472
[TBL] [Abstract][Full Text] [Related]
18. Esophageal small cell carcinoma without neuroendocrine features but with KIT and PDGFRA expression: KIT as a useful marker of this type of tumor.
Terada T
J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():132-5. PubMed ID: 24604264
[No Abstract] [Full Text] [Related]
19. Targeted therapy for cancer: the gastrointestinal stromal tumor model.
Balachandran VP; Dematteo RP
Surg Oncol Clin N Am; 2013 Oct; 22(4):805-21. PubMed ID: 24012400
[TBL] [Abstract][Full Text] [Related]
20. Pathologic diagnosis of large cell neuroendocrine carcinoma of the lung in an axillary lymph node: a case report with immunohistochemical and molecular genetic studies.
Terada T
Int J Clin Exp Pathol; 2013; 6(6):1177-9. PubMed ID: 23696939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
